


### About us

We are a leading Czech chemical-pharmaceutical company with a long-standing tradition. Our core activities include the research, development, production, and sale of generic active pharmaceutical ingredients (APIs) and other chemical products and specialties. We also specialise in contract manufacturing and development. With an export oriented focus, we ship up to 90% of our products to more than 80 countries worldwide, including European nations, the USA, India, Japan, China, Latin America, and others.



## Our values



Quality of Human Health



Social Responsibility



Environmental Protection



Customer-Centric Approach

# Global export reach



## **FARMAK** in numbers



Assets ≈ 45.25 million EUR



**Ebitda 2023** ≈ 5.38 million EUR



**Equity** ≈ 40.63 million EUR



Investments (2021–2023) ≈ 11.83 million EUR



Employees 299



Number of countries we export to ≈ 80



**Certifications** ISO 9001:2015 ISO 14001:2015



Customers  $\approx 200$ 






# We are part of strong Group

Jiří Žák has gradually expanded his business portfolio by founding additional companies. In 2012, he established the CZECH–GEN Group, bringing together all his businesses, including FARMAK. Today, the holding employs over 500 people and encompasses several companies. MedicProgress specializes in contract manufacturing and the innovative development of high-quality cosmetic products, food supplements, and medical devices. UNIVIT focuses on the production of veterinary medicines, while FARMAK MORAVIA is dedicated to manufacturing disinfectants. The business also includes planned real estate development projects and hospitality services. Each company within the group shares a common mission— enhancing human health and improving the quality of life in society.

### Our timeline



Independence and renaming to Farmakon, state-owned enterprise, and the addition of a veterinary medicine, biofactor supplement, and animal feed production plant in Uničov.


Takeover of the state-owned enterprise Farmakon n.p. and start of restructuring. Extension of the production programme with new substances thanks to the application of the results of the research and development department.

The first inspection of the FDA (Food and Drug Administration) for the registration of active pharmaceutical ingredients in US.

A new production unit built in plant 33 – the UNI Hall with QC laboratories and a new QA unit, research and development laboratories, including instrumentation – was awarded the Building of the Year 2004 in the Olomouc Region.

Construction of a new hall for final operations.

A new production unit, SAU 13.02, built in plant 13 for production from our own research and development.



Installation of the new Kilolab unit in accordance with cGMP.

Reconstruction of the hydrogenation unit in plant 21.

Reconstruction of production unit PJ 20.06 in building No. 33.

# We take responsibility for our environment

Being an environmentally and socially responsible company is a core principle of our philosophy. Workplace safety and environmental protection remain our highest priorities, which we address through our ESG strategy. Every year, we publish an environmental impact report to inform the public about our company's influence on its surroundings. In 2022, the internationally recognised sustainability rating agency EcoVadis awarded us a gold medal.

We pride ourselves on being a technologically innovative industrial company committed to sustainability—not only through environmentally friendly manufacturing but also through our fundamental corporate mission of supporting human health. As one of the largest employers in the region, we actively engage in charitable and community initiatives that enhance local social life. Our efforts were recognised in 2017 when we received the Sustainable Development Award from the Association of the Chemical Industry of the Czech Republic (SCHP ČR).





We strive to contribute to improving the quality of life in our community.

"As a successful company that has fulfilled many dreams, we feel a responsibility to share our success and use it for the benefit of society. We do this by supporting charitable initiatives and cultural activities. We fund non-profit organisations that assist people with disabilities, financially sponsor medical research, and engage senior citizens in community life through intergenerational programmes initiated by our company. These activities primarily take place in Olomouc, where FARMAK has been operating as a family business for over 30 years. We want our company's legacy to be evident not only in business success and our reputation as a good employer but also in our active contribution to the development of our community."

#### Bronislava Paučková

PR manager of FARMAK, a.s.
Vice-Chairwoman of the CZECH-GEN Group

### Our activities



Contract & In-house Manufacturing



Research & Development



Innovation & Growth

# Research & Development

The production and sale of APIs account for up to 95% of our company's total revenue. The synthesis and characterization of APIs are fundamental pillars of our business, and we emphasize strong innovation. We develop and optimize patent non-infringing synthesis routes (RoS – Route of Synthesis) for APIs and their intermediates before the expiry of original patents, as well as for substances with expired patents that remain commercially attractive. A portion of our capacity is dedicated to chemical specialties. We are fully equipped with the necessary instruments for substance analysis and purity verification. Selected results of our research activities are patented not only in the Czech Republic but also in Europe and the USA.





# Our production

Currently, the facility consists of 2 cGMP production halls with auxiliary buildings (QC/QA/R&D departments, hall of final operations, warehouses, water treatment system, etc.) with total area of 36,000 m². The total reactor capacity is approximately 100 m³, enabling the production of batch sizes from 100 grams up to 5 kg (kilolab), from 5 kg up to 20 kg (small API unit) and from 20 kg up to 250 kg (regular units).

# Our technological capabilities

In addition to common organic reactions at temperatures ranging from -15°C to 140°C, we are fully capable and equipped for Grignard reactions, cryogenic and high-temperature reactions (up to 300°C), low-pressure hydrogenation (up to 3 bar), and controlled crystallization for the required PSD of the final product through sieving, milling, and micronization. We are developing a fully equipped solid-state crystallography laboratory, which will ensure stable crystalline form, morphology, and PSD production.



# Contract Research & Manufacturing

We understand that every client has unique requirements. That's why we provide tailored solutions to meet the specific objectives of each project. Our professionalism and expertise across various chemical and pharmaceutical disciplines enable us to adapt to a wide range of needs in contract research and contract manufacturing. We are the ideal partner for companies seeking reliable and efficient production solutions. Operating under cGMP conditions, we develop, scale up, and manufacture products from just a few grams to several hundred kilograms. Choosing us means partnering with a company that values quality, innovation, and customer satisfaction.



## Our capabilities









#### Scale-up Laboratory

Entry-level research with reactors of 5–15 L, ensuring optimal reaction conditions.



A department for technology validation and small-scale production, equipped with cryogenic reactors (60 L), operating under cGMP standards

#### **Small API Unit**

A facility with 400 L reactors, enabling batch production from 5 to 25 kg, bridging the gap between Kilolab and full-scale manufacturing, in full compliance with cGMP


#### Standard production

Large-scale manufacturing with reactors ranging from 400 to 6,300 L, including centrifuges and filter dryers. We offer customisation of physical processes to meet customer needs, with full cGMP compliance.

### We are innovation-focused

In addition to established methods, the company also focuses on the exploration of new manufacturing technologies that enable efficient development and optimisation of scalable production processes, including flow chemistry (continuous reactors) and chromatographic separation techniques. We work closely with a number of leading universities and research institutions, which provides us with additional support in the implementation of innovative technologies.





# Quality management system

Inspected by authorities on regular basis













State Institute of Drugs and Good Practices













### FARMAK, a.s.

Address: Na vlcinci 16/3 Klasterní Hradisko 779 00 Olomouc Czech Republic





